Toor Amir A, Horton Morgan, Khalid Haniya, Krieger Elizabeth, Lai Tsung-Po, Spellman Stephen R, Levine John E, Saber Wael, Aviv Abraham, Stewart Valerie, Gadalla Shahinaz M
Harold C. Simmons Cancer Center, University of Texas Southwestern, Dallas, TX.
Lehigh Valley Health Network, Allentown, PA.
medRxiv. 2025 Jan 22:2025.01.20.24319630. doi: 10.1101/2025.01.20.24319630.
T cell proliferation and repertoire reconstitution is a hallmark of successful hematopoietic cell transplantation (HCT). This process may be modeled as a dynamical system and in such a system, precise telomere length (TL) measurement may reflect the proliferative capacity of donor T cells. TL for different chromosomes span a few orders of magnitude, and different T cell clones will display variable TL; these differences across the population are not represented when examining average TL. This study aims to develop a method that integrates the entire spectrum of TL observed within a sample to better understand the influence on clinical outcomes following HCT.
To better reflect the entire span of TL, we used data generated using the TeLSA PCR technique that provided discrete measurments of individual telomeres for each DNA sample for 72 stem cell transplant (SCT) donor-recipient pairs. Donor and recipient TeSLA TL measurements was performed on samples taken before and 90 days post HCT, respectively. Set correspondence mathematical techniques and area under the curve (AUC) calculations were used to measured donor-recipient TL differences (delta-TL) incorporating the full distribution of measured TL from each sample.
Telomere band lengths ranged from 350 basepairs (BP) to 16.7 kilobases with a logarithmically declining distribution in all samples when arrayed in a descending order. Set correspondence methods yielded TL averages which were highly correlated with AUC calculations (r >0.9, p<0.001 for all). The method predicted patient overall survival (P-log rank <0.0001). HCT recipients with intermediate degrees of telomere attrition (25-75 percentile) post-HCT experienced the best outcomes (2 years overall survival; OS=92%), whilst donors with the least (<25 percentile; 2 years OS=33%; adjusted HR intermediate shortening=9.3, p=0.001) and the greatest (>75 percentile; 2 years OS=59%; adjusted HR=6.0, p=0.01) shortening had worse outcomes. By contrast, using the traditional method based on donor-recipient difference in TeSLA mean telomere length did not demonstrate survival association in this small sample set (p log-rank=0.95).
The findings described herein suggest that the degree of donor telomere attrition may reflect T cell proliferation and alloreactivity following transplant. Accounting for the entire span of telomere lengths, could better identify post-transplant risk groups.
T细胞增殖和谱系重建是成功进行造血细胞移植(HCT)的标志。这个过程可以被建模为一个动态系统,在这样的系统中,精确的端粒长度(TL)测量可能反映供体T细胞的增殖能力。不同染色体的端粒长度跨度达几个数量级,不同的T细胞克隆会显示出可变的端粒长度;在检查平均端粒长度时,群体中的这些差异并未得到体现。本研究旨在开发一种方法,整合样本中观察到的端粒长度的整个谱,以更好地理解其对HCT后临床结果的影响。
为了更好地反映端粒长度的整个范围,我们使用了通过TeLSA PCR技术生成的数据,该技术为72个干细胞移植(SCT)供体 - 受体对的每个DNA样本提供了单个端粒的离散测量值。分别在HCT前和HCT后90天采集的样本上进行供体和受体的TeSLA端粒长度测量。使用集合对应数学技术和曲线下面积(AUC)计算来测量供体 - 受体端粒长度差异(δ - TL),纳入每个样本测量的端粒长度的全部分布。
当按降序排列时,所有样本中的端粒带长度范围从350个碱基对(bp)到16.7千碱基,呈对数下降分布。集合对应方法得出的端粒长度平均值与AUC计算高度相关(所有r>0.9,p<0.001)。该方法预测了患者的总生存期(P - 对数秩<0.0001)。HCT后端粒磨损程度处于中等水平(第25 - 75百分位数)的受者预后最佳(2年总生存期;OS = 92%),而端粒缩短最少(<第25百分位数;2年OS = 33%;调整后HR 中等缩短 = 9.3,p = 0.001)和最多(>第75百分位数;2年OS = 59%;调整后HR = 6.0,p = 0.01)的供体预后较差。相比之下,在这个小样本集中,使用基于供体 - 受体TeSLA平均端粒长度差异的传统方法未显示出生存相关性(p对数秩 = 0.95)。
本文所述的研究结果表明,供体端粒磨损程度可能反映移植后T细胞的增殖和同种异体反应性。考虑端粒长度的整个范围,可以更好地识别移植后的风险组。